Allergocrom (Sodium Cromoglicate)

Allergocrom is employed in the management of allergic conditions that affect the nasal passages.

• Seasonal allergic rhinitis (hay fever), providing relief from sneezing, nasal congestion, and itchy nose during pollen seasons.
• Perennial allergic rhinitis, helping control symptoms that persist year‑round due to indoor allergens such as dust mites or pet dander.
• Allergic conjunctivitis with nasal involvement, reducing watery eyes and nasal itching when ocular and nasal symptoms occur together.
• Prevention of nasal symptoms triggered by known allergens, used prophylactically before exposure to pollen, mold spores, or animal dander.
• Adjunct therapy for patients using other antiallergic medications, allowing a combined approach to manage moderate to severe allergic rhinitis.

• Sodium cromoglicate stabilizes mast cells by inhibiting calcium‑dependent degranulation, which reduces the release of histamine, leukotrienes, and other inflammatory mediators. By preventing this cellular activation, the drug limits the cascade that leads to nasal mucosal edema, itching, and secretions associated with allergic reactions. The action is localized to the nasal mucosa when administered intranasally, providing targeted antiallergic effect without systemic immunosuppression.

Adverse reactions to intranasal sodium cromoglicate are generally mild, but rare serious events have been reported.

Common

• Nasal irritation or a burning sensation that may be felt shortly after each dose.
• Sneezing or a mild, transient cough occurring during or after administration.
• Unpleasant taste or throat irritation that usually resolves without intervention.
• Mild headache that is generally short‑lived and does not require treatment.

Serious

• Severe allergic reaction (anaphylaxis) with difficulty breathing, swelling of the throat, or a rapid drop in blood pressure.
• Persistent nasal bleeding that does not stop with gentle pressure.
• Swelling of the face, lips, or tongue that may interfere with breathing or speech.
• Vision changes, eye irritation, or ocular redness that develop shortly after use.

When using Allergocrom, certain precautions should be observed to ensure safe and effective treatment.

• Do not use if you have a known hypersensitivity to sodium cromoglicate or any component of the formulation.
• Avoid administration in the presence of nasal infections or severe nasal congestion without medical advice.
• Use the product only as directed; excessive dosing may increase the risk of local irritation.
• Pregnant or breastfeeding individuals should consult a healthcare professional before starting therapy.
• Children and elderly patients may require special consideration regarding dosing and monitoring.
• If symptoms persist or worsen, discontinue use and seek medical evaluation.

Sodium cromoglicate may interact with other medications or substances; awareness of potential interactions helps maintain therapeutic benefit.

Avoid

• Concurrent use with other mast cell stabilizers without physician supervision.
• Combining with systemic antihistamines that may mask local irritation signs.
• Avoid using with nasal sprays containing alcohol or irritants that could exacerbate mucosal irritation.

Use with caution

• Use with nasal decongestants; monitor for increased nasal dryness.
• Use with inhaled corticosteroids; observe for additive local effects.
• Use with other antiallergic eye drops; assess for cumulative irritation.
• Use with oral antihistamines; monitor for overlapping sedation or drowsiness.
• Use with caution in patients taking anticoagulants; monitor for any unusual nasal bleeding.